Glukokortikoid Reseptör Geni (NR3C1) ve Meme Kanserinde Rolü

Year 2018, Volume: 1 Issue: 2, 61 - 70, 15.10.2018

Zehra Kaya

Abstract

Meme kanseri oldukça heterojen bir kanser olup, kanserin orijinine bağlı olarak adenokarsinom,

duktal, lobular ve meme ucu karsinom olarak sınıflandırılabilir. Histolojik tiplendirme dışında

meme kanseri östrojen reseptör (ER), progesteron reseptör (PR) ve epidermal büyüme faktörü

reseptör 2 (ERBB2/HER2) gibi düzenleyicilerdeki mutasyonlar ile ayrıca moleküler olarak

sınıflandırılabilir. Glukokortikoidler (GC) meme kanseri dahil birçok hastalığın tedavisinde

kullanılmaktadır. GC’ler kemoterapinin yan etkilerini azaltmak ve normal dokuyu meme

kanserinde genotoksik ilaçların uzun süreli etkilerine karşı korumak için sıklıkla bir adjuvan

tedavi olarak uygulanır. GC’lerin etkileri genellikle glukokortikoid reseptör (GR) aracılığı

ile gerçekleşir. GR etkilerinin anlaşılması meme kanseri tedavisindeki potansiyel ilgisinin

tartışılmasında önemli olacaktır. Bu derlemenin amacı, meme kanserinin gelişmesi ve

ilerlemesinde GR’nin etkilerini tanımlamaktır.

Keywords

Glukokortikoid, Glukokortikoid reseptör, Meme kanseri, Kanser

References

• 1. Edge SB, Byrd DR, Compton CC (Eds.), AJCC Cancer Staging Manual, 7th ed., Springer, New York, NY, Breast 2010; pp. 347-376. 2. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets, Proc Natl Acad Sci 2003; 100: 8418-8423. 3. Lecoq L, Vincent P, Lavoie-Lamoureux A, et al. Genomic and non-genomic effects of dexamethasone on equine peripheral blood neutrophils. Vet Immunol Immunopathol 2009; 15: 126-31. 4. Moutsatsou P, Papavassiliou AG. The glucocorticoid receptor signalling in breast cancer. J Cell Mol Med 2008; 12: 145-63. 5. Simoncini T, Genazzani AR. Non-genomic actions of sex steroid hormones. Eur J Endocrinol 2003; 148: 281-92. 6. Duma D, Jewell CM, Cidlowski JA. Multiple glucocorticoid receptor isoforms and mechanisms of post-translational modification. J Steroid Biochem Mol Biol 2006; 102: 11-21. 7. Sundahl N, Clarisse D, Bracke M, et al. eCollection 2016. Selective glucocorticoid receptoractivating adjuvant therapy in cancer treatments. Oncoscience 2016; 3: 188-202. 8. McNamara KM, Kannai A, Sasano H. Possible roles for glucocorticoid signalling in breast cancer. Mol Cell Endocrinolol 2018; 466: 38-50. 9. Beato M, Sanchez-Pacheco A. Interaction of steroid hormone receptors with the transcription initiation complex. Endocr Rev 1996;17: 587-609. 10. Hollenberg, SM, Weinberger C, et al. Primary structure and expression of a functional human glucocorticoid receptor cDNA. Nature 1985; 318: 635-641. 11. Encio IJ, Detera-Wadleigh SD. The genomic structure of the human glucocorticoid receptor. J Biol Chem 1991; 266: 7182-7188. 12. Oakley RH, Sar M, Cidlowski JA. The human glucocorticoid receptor beta isoform. Expression, biochemical properties, and putative function. J Biol Chem 1996; 271: 9550-9559. 13. Kino T, Manoli I, Kelkar S, et al. Glucocorticoid receptor (GR) has intrinsic, GR-independent transcriptional activity. Biochem Biophys Res Commun 2009; 381: 671-675. 14. K. Hecht J, Carlstedt-Duke P, Stierna J, et al. Evidence that the beta-isoform of the human glucocorticoid receptor does not act as a phsiologically significant repressor, J Biol Chem 1997; 272: 26659. 15. Yudt MR, Jewell CM, Bienstock RJ, et al. Molecular origins fort he dominant negative function of human glucocorticoid receptor beta. Mol Cell Biol 2003; 23: 4319. 16. Oakley RH, Jewell CM, Yudt MR, et al. The dominant negative activity of the human glucocorticoid receptor beta isoform. Specificity and mechanisms of action J Biol Chem 1999; 274: 27857. 17. Goulding NJ. The molecular complexityof glucocorticoid actions in inflammation – a four-ring circus. Curr Opin Pharmacol 2004; 4: 629-636. 18. Rivers C, Levy A, Hancock J, et al. Insertion of an amino acid in the DNA-binding domain of the glucocorticoid receptor as a result of alternative splicing, J Clin Endocrinol Metab 1999; 84: 4283. 19. Hollenberg SM, Evans RM. Multiple and cooperative transactivation domains of the human glucocorticoid receptor. Cell 1988; 55: 899-906. 20. Gross KL, Cidlowski JA. Tissue-specific glucocorticoid action: a family affair, Trends Endocrinol Metab 2008; 19: 331-339. 21. Adcock IM, Ito K. Molecular mechanisms of corticosteroid actions, Monaldi Arch Chest Dis 2000; 55: 256. 22. Morishima Y, Murphy PJ, Li DP, et al. Stepwise assembly of a glucocorticoid receptor hsp90 heterocomplex resolves two sequential ATPdependent events involving first hsp70 and then hsp90 in opening of the steroid binding pocket. J Biol Chem 2000; 275:18054. 23. Schaaf MJ, Cidlowski JA. Molecular determinants of glucocorticoid receptor mobility in living cells: the importance of ligand affinity. Mol Cell Biol 2003; 23: 1922-1934. 24. Holaska JM, Black BE, Rastinejad F, et al. Ca2+ dependent nuclear export mediated by calreticulin. Mol Cell Biol 2002; 22: 6286-6297. 25. Kino T, Souvatzoglou E, De Martino MU, et al. Protein 14-3-3σ interacts with and favors cytoplasmic subcellular localization of the glucocorticoid receptor, acting as a negative regulator of the glucocorticoid signaling pathway. J Biol Chem 2003; 278: 25651-25656. 26. Boldizar F, Talamber G, Szabo M, et al. Emerging pathways of non-genomic glucocorticoid (GC) signalling in T cells. Immunobiology 2010; 215: 521-526. 27. Z. Wang J, Frederick MJ. Garabedian, Deciphering the phosphorylation ―code‖ of the glucocorticoid receptor in vivo. J Biol Chem 2002; 277: 26573. 28. Adcock IM, Caramori G. Cross-talk between pro-inflammatory transcription factors and glucocorticoids, Immunol Cell Biol 2001; 79: 376. 29. Kino T, Chrousos GP. Tissue-specific glucocorticoid resistancehypersensitivity syndromes: multifactorial states of clinical importance. J Allergy Clin Immunol 2002; 109: 609-613. 30. Barnes PJ, Adcock IM. How do corticosteroids work in asthma? Ann Intern Med 2003; 139: 59-370. 31. Kinyamu HK, Chen J, Archer TK. Linking the ubiquitin– proteasome pathway to chromatin remodeling/modification by nuclear receptors. J Mol Endocrinol 2005; 34: 281-297. 32. Le DY, Mincheneau N, Le GP, et al. Potentiation of glucocorticoid receptor transcriptional activity by sumoylation. Endocrinology 2002; 143: 3482-3489. 33. Nader N, Chrousos GP, Kino T. Circadian rhythm transcription factor CLOCK regulates the transcriptional activity of the glucocorticoid receptor by acetylating its hinge region lysine cluster: potential physiological implications. Faseb J 2009; 23: 1572-1583. 34. Galliher-Beckley AJ, Williams JG, Collins JB, et al. Glycogen synthase kinase 3 beta-mediated serine phosphorylation of the human glucocorticoid receptor redirects gene expression profiles. Mol Cell Biol 2008; 28: 7309-7322. 35. Seckl JR. Prenatal glucocorticoids and long-term programming. Eur J Endocrinol 2004; 151: 49-62. 36. Horwitz KB, Costlow ME, McGuire WL. MCF- 7; a human breast cancer cell line with estrogen, androgen, progesterone, and glucocorticoid receptors. Steroids 1975; 26:785-795. 37. Moran TJ, Gray S, Mikosz CA, et al. The glucocorticoid receptor mediates a survival signal in human mammary epithelial cells. Cancer Res 2000; 60: 867-872. 38. Mikosz CA, Brickley DR, Sharkey MS, et al. Glucocorticoid receptor-mediated protection from apoptosis is associated with induction of the serine/ threonine survival kinase gene, sgk-1. J Biol Chem 2001; 276: 16649-16654. 39. Herr I, Pfitzenmaier J. Glucocorticoid use in prostate cancer and other solid tumours: implications for effectiveness of cytotoxic treatment and metastases. Lancet Oncol 2006; 7: 425-430. 40. Wu W, Chaudhuri S, Brickley DR, et al. Microarray analysis reveals glucocorticoidregulated survival genes that are associated with inhibition of apoptosis in breast epithelial cells. Cancer Res 2004; 64: 1757-1764. 41. Sherlock P, Hartmann WH. Adrenal steroids and the pattern of metastases of breast cancer. JAMA 1962; 181: 313-317 42. Pang D, Kocherginsky M, Krausz T, et al. Dexamethasone decreases xenograft response to Paclitaxel through inhibition of tumor cell apoptosis. Cancer Biol Ther 2006; 5: 933-940. 43. Skor MN, Wonder EL, Kocherginsky M, et al. Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer. Clin Cancer Res 2013; 19: 6163-6172. 44. Pan D, Kocherginsky M, Conzen SD. Activation of the glucocorticoid receptor is associated with poor prognosis in estrogen receptor-negative breast cancer. Cancer Res 2011; 71: 6360-6370 45. Spiegel D, Butler LD, Giese-Davis J, et al. Effects of supportive-expressive group therapy on survival of patients with metastatic breast cancer – a randomized prospective trial. Cancer 2007; 110: 1130-1138. 46. Zhang C, Wenger T, Mattern J, et al. Clinical and mechanistic aspects of glucocorticoid induced chemotherapy resistance in the majority of solid tumors. Cancer Biol Ther 2007; 6: 278-287. 47. Park J, Euhus DM, Scherer PE. Paracrine and endocrine effects of adipose tissue on cancer development and progression. Endocr Rev 2011; 32: 550-570. 48. Masuzaki H, Paterson J, Shinyama H, et al. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001; 294: 2166- 2170. 49. Law ME, Corsino PE, Jahn SC, et al. Glucocorticoids and histone deacetylase inhibitors cooperate to block the invasiveness of basal-like breast cancer cells through novel mechanisms. Oncogene 2013; 32:1316-1329. 50. Yano A, Fujii Y, Iwai A, et al. Glucocorticoids suppress tumor angiogenesis and in vivo growth of prostate cancer cells, Clin Cancer Res 2006; 12: 3003-3009. 51. Lin KT, Yeh YM, Chuang CM, et al. Glucocorticoids mediate induction of microRNA-708 to suppress ovarian cancer metastasis through targeting Rap1B, Nat Commun 2015; 6: 5917. 52. Lien HC, Lu YS, Cheng AL, et al. Differential expression of glucocorticoid receptor in human breast tissues and related neoplasms. J Pathol 2006; 209: 317-327. 53. Nesset KA, Perri AM, Mueller CR. Frequent promoter hypermethylation and expression reduction of the glucocorticoid receptor gene in breast tumors. Epigenetics 2014; 9: 851-859. 54. Lietzen LW, Ahern T, Christiansen P, et al. Glucocorticoid prescriptions and breast cancer recurrence: a Danish nationwide prospective cohort study. Ann Oncol 2014; 25: 2419-2425. 55. Sorensen GV, Cronin-Fenton DP, Sorensen HT, et al. Use of glucocorticoids and risk of breast cancer: a Danish population-based case-control study. Breast Cancer Res 2012; 14: 21-30.